Localization and expression of vmat2 aross mammalian species. A translational guide for its visualization and targeting in health and disease.

Advances in Pharmacology

Volumn 68, Issue , 2013, Pages 319-334

  Schafer, Martin K H ^a   Weihe, Eberhard ^a   Eiden, Lee E ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Dopamine; Epinephrine; Histamine; Neuroendocrine tumors (NETs); Norepinephrine; Pancreas; Serotonin; Tetrabenazine; VMAT2

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; LEVODOPA; PRAMIPEXOLE; RESERPINE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

ADRENAL MEDULLA; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; DEPRESSION; DRUG WITHDRAWAL; ENTEROCHROMAFFIN LIKE CELL; ENZYME SPECIFICITY; EXTRACELLULAR SPACE; GENE DOSAGE; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; IMMOBILIZATION STRESS; IN VIVO STUDY; MAMMAL; MAST CELL; MONOAMINERGIC NERVE; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PANCREAS ISLET BETA CELL; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN TARGETING; RNA TRANSLATION; SPECIES COMPARISON; SPECIES DIFFERENCE; STELLATE GANGLION; THALAMOCORTICAL TRACT;

DOPAMINE; EPINEPHRINE; HISTAMINE; NEUROENDOCRINE TUMORS (NETS); NOREPINEPHRINE; PANCREAS; SEROTONIN; TETRABENAZINE; VMAT2;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BRAIN; DIGESTIVE SYSTEM; HUMANS; PERIPHERAL NERVOUS SYSTEM; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84884309471     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411512-5.00015-4     Document Type: Chapter

References (59)

1. Anlauf M., Eissele R., Schafer M.K., Eiden L.E., Arnold R., Pauser U., et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. Journal of Histochemistry and Cytochemistry 2003, 51(8):1027-1040.
2. Anlauf M., Schafer M.K., Depboylu C., Hartschuh W., Eiden L.E., Kloppel G., et al. The vesicular monoamine transporter 2 (VMAT2) is expressed by normal and tumor cutaneous mast cells and Langerhans cells of the skin but is absent from Langerhans cell histiocytosis. Journal of Histochemistry and Cytochemistry 2004, 52(6):779-788.
3. Anlauf M., Schafer M.K., Schwark T., von Wurmb-Schwark N., Brand V., Sipos B., et al. Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis. Journal of Histochemistry and Cytochemistry 2006, 54(2):201-213.
4. Apostolova G., Dechant G. Development of neurotransmitter phenotypes in sympathetic neurons. Autonomic Neuroscience 2009, 151(1):30-38. 10.1016/j.autneu.2009.08.012.
5. Apostolova G., Loy B., Dorn R., Dechant G. The sympathetic neurotransmitter switch depends on the nuclear matrix protein Satb2. Journal of Neuroscience 2010, 30(48):16356-16364. 10.1523/JNEUROSCI.3502-10.2010.
6. Axelrod J. Doing research in the Intramural Program of the National Institutes of Health. Perspectives in Biology and Medicine 1986, 29(3 Pt 2):S131-S137.
7. Balan I.S., Ugrumov M.V., Calas A., Mailly P., Kreiger M., Thibault J. Tyrosine hydroxylase-expressing and/or aromatic l-amino acid decarboxylase-expressing neurons in the mediobasal hypothalamus of perinatal rats: Differentiation and sexual dimorphism. The Journal of Comparative Neurology 2000, 425:167-176.
8. Bohnen N.I., Albin R.L., Koeppe R.A., Wernette K.A., Kilbourn M.R., Minoshima S., et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. Journal of Cerebral Blood Flow and Metabolism 2006, 26(9):1198-1212. 10.1038/sj.jcbfm.9600276.
9. 11C-dihydrotetrabenazine beta-cell imaging. Journal of Nuclear Medicine 2010, 51(9):1335-1336. 10.2967/jnumed.110.077602.
10. Brown J.M., Hanson G.R., Fleckenstein A.E. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants. Journal of Pharmacology and Experimental Therapeutics 2001, 296:762-767.
11. Cases O., Lebrand C., Giros B., Vitalis T., De Maeyer E., Caron M.G., et al. Plasma membrane transporters of serotonin, dopamine, and norepinephrine mediate serotonin accumulation in atypical locations in the developing brain of monoamine oxidase A knock-outs. Journal of Neuroscience 1998, 18(17):6914-6927.
12. Duerr J.S., Frisby D.L., Gaskin J., Duke A., Asermely K., Huddleston D., et al. The cat-1 gene of Caenorhabditis elegans encodes a vesicular monoamine transporter required for specific monoamine-dependent behaviors. Journal of Neuroscience 1999, 19:72-84.
13. Eiden L.E., Schafer M.K., Weihe E., Schutz B. The vesicular amine transporter family (SLC18): Amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflügers Archiv 2004, 447(5):636-640.
14. Eiden L.E., Weihe E. VMAT2: A dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Annals of the New York Academy of Sciences 2011, 1216:86-98. 10.1111/j.1749-6632.2010.05906.x.
15. Erickson J.D., Eiden L.E., Hoffman B. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10993-10997.
16. Erickson J.D., Eiden L.E., Schäfer M.K.-H., Weihe E. Reserpine- and tetrabenazine-sensitive transport of 3H-histamine by the neuronal isoform of the vesicular monoamine transporter. Journal of Molecular Neuroscience 1995, 6:277-287.
17. Erickson J.D., Schäfer M.K.-H., Bonner T.I., Eiden L.E., Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:5166-5171.
18. Fon E.A., Pothos E.N., Sun B.-C., Killeen N., Sulzer D., Edwards R.H. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997, 19:1271-1283.
19. Francis N.J., Landis S.C. Cellular and molecular determinants of sympathetic neuron development. Annual Review of Neuroscience 1999, 22:541-566.
20. Frank S., Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs 2010, 70(5):561-571. (Review). 10.2165/11534430-000000000-00000.
21. Freeby M., Goland R., Ichise M., Maffei A., Leibel R., Harris P. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diabetes, Obesity & Metabolism 2008, 10(Suppl. 4):98-108. 10.1111/j.1463-1326.2008.00943.x.
22. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Annals of Neurology 1996, 40(6):873-884. 10.1002/ana.410400609.
23. Gershon M.D. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel. Alimentary Pharmacology and Therapeutics 1999, 13:15-30.
24. Guillot T.S., Miller G.W. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Molecular Neurobiology 2009, 39(2):149-170. 10.1007/s12035-009-8059-y.
25. Ichise M., Harris P.E. Imaging of beta-cell mass and function. Journal of Nuclear Medicine 2010, 51(7):1001-1004. 10.2967/jnumed.109.068999.
26. Ikemoto K., Nagatsu I., Nishimura A., Nishi K., Arai R. Do all of human midbrain tyrosine hydroxylase neurons synthesize dopamine?. Brain Research 1998, 805(1-2):255-258.
27. 11C]dihydrotetrabenazine binding in rat striatum: Sensitivity to dopamine concentrations. Nuclear Medicine and Biology 2010, 37(1):3-8. 10.1016/j.nucmedbio.2009.08.013.
28. Kitahama K., Ikemoto K., Jouvet A., Nagatsu I., Geffard M., Okamura H., et al. Dopamine synthesizing enzymes in paraventricular hypothalamic neurons of the human and monkey (Macaca fuscata). Neuroscience Letters 1998, 243:1-4.
29. Komori K., Fujii T., Nagatsu I. Do some tyrosine hydroxylase-immunoreactive neurons in the human ventrolateral arcuate nucleus and globus pallidus produce only L-dopa?. Neuroscience Letters 1991, 133(2):203-206.
30. Kung H.F., Lieberman B.P., Zhuang Z.P., Oya S., Kung M.P., Choi S.R., et al. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine. Nuclear Medicine and Biology 2008, 35(8):825-837. 10.1016/j.nucmedbio.2008.08.004.
31. Lebrand C., Cases O., Wehrlé R., Blakely R.D., Edwards R.H., Gaspar P. Transient developmental expression of monoamine transporters in the rodent forebrain. The Journal of Comparative Neurology 1998, 401:506-524.
32. Lebrand C., Gaspar P., Nicolas D., Hornung J.P. Transitory uptake of serotonin in the developing sensory pathways of the common marmoset. The Journal of Comparative Neurology 2006, 499(4):677-689. 10.1002/cne.21137.
33. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G.G., Eisenberg D., et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992, 70:539-551.
34. Lohoff F.W. Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders. Methods in Molecular Biology 2010, 637:165-180. 10.1007/978-1-60761-700-6_9.
35. Merickel A., Edwards R.H. Transport of histamine by vesicular monoamine transporter-2. Neuropharmacology 1995, 34:1543-1547.
36. 18F-fluoropropyl-dihydrotetrabenazine and PET. Journal of Nuclear Medicine 2012, 53(6):908-916. 10.2967/jnumed.111.100545.
37. Peter D., Vu T., Edwards R.H. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. Journal of Biological Chemistry 1996, 271:2979-2986.
38. Raffo A., Hancock K., Polito T., Xie Y., Andan G., Witkowski P., et al. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine. Journal of Endocrinology 2008, 198(1):41-49. 10.1677/JOE-07-0632.
39. Rilstone J.J., Alkhater R.A., Minassian B.A. Brain dopamine-serotonin vesicular transport disease and its treatment. New England Journal of Medicine 2013, 368(6):543-550. (Research Support, Non-U.S. Gov't). 10.1056/NEJMoa1207281.
40. Saisho Y., Harris P.E., Butler A.E., Galasso R., Gurlo T., Rizza R.A., et al. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. Journal of Molecular Histology 2008, 39(5):543-551. 10.1007/s10735-008-9195-9.
41. Schafer M.K., Hartwig N.R., Kalmbach N., Klietz M., Anlauf M., Eiden L.E., et al. Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: Implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models. Diabetologia 2013, 56(5):1047-1056. 10.1007/s00125-013-2847-7.
42. Schäfer M.K.-H., Schütz B., Weihe E., Eiden L.E. Target-independent cholinergic differentiation in the rat sympathetic nervous system. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4149-4154.
43. Schuldiner S. A molecular glimpse of vesicular transporters. Journal of Neurochemistry 1994, 62:2067-2078.
44. Schuldiner S., Shirvan A., Linial M. Vesicular neurotransmitter transporters: From bacteria to humans. Physiological Reviews 1995, 75:369-392.
45. Schütz B., Schäfer M.K.-H., Eiden L.E., Weihe E. Ontogeny of vesicular amine transporter expression in the rat: New perspectives on aminergic neuronal and neuroendocrine differentiation. Advances in Pharmacology 1998, 42:903-908.
46. Schütz B., Schäfer M.K.-H., Eiden L.E., Weihe E. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut. Brain Research. Developmental Brain Research 1998, 106:181-204.
47. Souza F., Simpson N., Raffo A., Saxena C., Maffei A., Hardy M., et al. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. Journal of Clinical Investigation 2006, 116(6):1506-1513. 10.1172/JCI27645.
48. Suzuki M., Desmond T.J., Albin R.L., Frey K.A. Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers. Synapse 2001, 41(4):329-336. 10.1002/syn.1089.
49. Tashiro Y., Sugimoto T., Hattori T., Uemura Y., Nagatsu I., Kikuchi H., et al. Tyrosine hydroxylase-like immunoreactive neurons in the striatum of the rat. Neuroscience Letters 1989, 97(1-2):6-10.
50. Tillinger A., Sollas A., Serova L.I., Kvetnansky R., Sabban E.L. Vesicular monoamine transporters (VMATs) in adrenal chromaffin cells: Stress-triggered induction of VMAT2 and expression in epinephrine synthesizing cells. Cellular and Molecular Neurobiology 2010, 30(8):1459-1465. 10.1007/s10571-010-9575-z.
51. Ugrumov M.V. Hypothalamic monoaminergic systems in ontogenesis: Development and functional significance. International Journal of Developmental Biology 1997, 41:809-816.
52. Ugrumov M.V. Non-dopaminergic neurons partly expressing dopaminergic phenotype: Distribution in the brain, development and functional significance. Journal of Chemical Neuroanatomy 2009, 38(4):241-256. 10.1016/j.jchemneu.2009.08.004.
53. Varoqui H., Erickson J.D. Vesicular neurotransmitter transporters. Molecular Neurobiology 1997, 15:165-191.
54. Weihe E., Schafer M.K., Erickson J.D., Eiden L.E. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. Journal of Molecular Neuroscience 1994, 5(3):149-164. 10.1007/BF02736730.
55. Weihe E., Schutz B., Hartschuh W., Anlauf M., Schafer M.K., Eiden L.E. Co-expression of cholinergic and noradrenergic phenotypes in human and non-human autonomic nervous system. The Journal of Comparative Neurology 2005, 492:370-379.
56. Weihe E., Depboylu C., Schutz B., Schafer M.K., Eiden L.E. Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression. Cell and Molecular Neurobiology 2006, 26:659-678.
57. Winkler H., Apps D.K., Fischer-Colbrie R. The molecular function of adrenal chromaffin granules: Established facts and unresolved topics. Neuroscience 1986, 18:261-290.
58. Zubieta J.-K., Huguelet P., Ohl L.E., Koeppe R.A., Kilbourn M.R., Carr J.M., et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: Sex differences and cognitive correlates. The American Journal of Psychiatry 2000, 157:1619-1628.
59. Zubieta J.-K., Taylor S.F., Huguelet P., Koeppe R.A., Kilbourn M.R., Frey K.A. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biological Psychiatry 2001, 49:110-116.